Enliven Therapeutics (ELVN) Stock Price & Analysis

ELVN$48.80+0.49 +1.01%
BiotechnologyGrowth Stock
Compare
Market cap$3.59BEnterprise value$3.62BRevenue (TTM)$0Market position—

Score

68
Bullish
Value
58
Quality
47
Growth
100

AI Analysis

Snapshot

Enliven Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 68/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~56% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

58
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Enliven Therapeutics, Inc. (ELVN) last printed $48.80. Equity value is $3.59B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Enliven Therapeutics (ELVN) Stock Price & Analysis

ELVN price $48.80 +0.49 +1.01%

Ticker
ELVN
Price
$48.80
Change
+0.49 +1.01%
Market cap
$3.59B
Dividend yield
0.00%
Beta
0.24
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
58
Quality
47
Growth
100

Stocklytics score rationale: value 58, quality 47, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener